![]() |
Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
More... |
Re: Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer
The report seems to imply it's effective for both primary liver cancer and other cancers that metastasized to the liver.
|
| All times are GMT -7. The time now is 06:23 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021